Initial phase I trial data involving oleclumab monotherapy remain unpublished, but in combination with durvalumab (anti-PD-L1), several trials were withdrawn due to reportedly low ORRs and one phase II trial involving ovarian cancer participants reported a DCR of only 27% [278]. This evidence concerns the gene CD274 and ovarian cancer.